MX2017013434A - Composiciones antibacterianas. - Google Patents

Composiciones antibacterianas.

Info

Publication number
MX2017013434A
MX2017013434A MX2017013434A MX2017013434A MX2017013434A MX 2017013434 A MX2017013434 A MX 2017013434A MX 2017013434 A MX2017013434 A MX 2017013434A MX 2017013434 A MX2017013434 A MX 2017013434A MX 2017013434 A MX2017013434 A MX 2017013434A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
antibacterial compositions
tazobactam
cefepime
Prior art date
Application number
MX2017013434A
Other languages
English (en)
Inventor
Vithalbhai Patel Mahesh
Deo Keshav
Nandlal Nagori Rajendra
Dattatraya Yeole Ravindra
Chauhan Bhaskar
Baburao Nandanwar Manohar
Kansagara Atul
Ahmed Iftekhar PATEL Muftedar
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2017013434A publication Critical patent/MX2017013434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas que comprenden cefepima o una sal farmacéuticamente aceptable del mismo, tazobactam o una sal farmacéuticamente aceptable del mismo, y arginina o una sal farmacéuticamente aceptable del mismo; y se describe su uso en el tratamiento, control o prevención de la infección bacteriana.
MX2017013434A 2016-03-31 2017-03-31 Composiciones antibacterianas. MX2017013434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621011250 2016-03-31
PCT/IB2017/051871 WO2017168393A1 (en) 2016-03-31 2017-03-31 Antibacterial compositions

Publications (1)

Publication Number Publication Date
MX2017013434A true MX2017013434A (es) 2018-01-30

Family

ID=58664745

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013434A MX2017013434A (es) 2016-03-31 2017-03-31 Composiciones antibacterianas.

Country Status (13)

Country Link
US (2) US20180064722A1 (es)
EP (1) EP3270925B1 (es)
JP (1) JP6552648B2 (es)
KR (1) KR102417756B1 (es)
CN (1) CN107835686A (es)
AU (1) AU2017242134B2 (es)
BR (1) BR112017022870A2 (es)
CA (1) CA2983250C (es)
ES (1) ES2905979T3 (es)
MX (1) MX2017013434A (es)
MY (1) MY198774A (es)
WO (1) WO2017168393A1 (es)
ZA (1) ZA201706947B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847501A (zh) * 2016-03-31 2018-03-27 沃克哈特有限公司 抗菌组合物以及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565456A (zh) * 2003-06-14 2005-01-19 张哲峰 一种头孢吡肟抗菌组合药物
EP2015755A4 (en) * 2006-04-28 2010-02-24 Wockhardt Ltd ENHANCED TREATMENT FOR TREATING BACTERIAL RESISTANT INFECTIONS
JP2011514902A (ja) * 2008-03-04 2011-05-12 エラン・ファルマ・インターナショナル・リミテッド 抗感染剤の安定な液体配合物および調節した抗感染剤投与計画
MX356373B (es) * 2011-05-28 2018-05-25 Wockhardt Ltd Composiciones que comprenden un agente antibacterial y tazobactam.
CN102743388B (zh) * 2012-05-15 2014-05-28 南京优科生物医药有限公司 一种抗产生β内酰胺酶细菌的组合物
KR102226197B1 (ko) * 2013-03-15 2021-03-11 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
EP3268001A1 (en) * 2016-03-31 2018-01-17 Wockhardt Limited Antibacterial compositions
CN107847501A (zh) * 2016-03-31 2018-03-27 沃克哈特有限公司 抗菌组合物以及方法

Also Published As

Publication number Publication date
EP3270925B1 (en) 2021-11-24
CA2983250A1 (en) 2017-10-05
US20240325406A1 (en) 2024-10-03
AU2017242134A1 (en) 2017-11-02
WO2017168393A1 (en) 2017-10-05
ES2905979T3 (es) 2022-04-12
AU2017242134B2 (en) 2022-12-01
BR112017022870A2 (pt) 2018-07-17
RU2017144215A (ru) 2019-06-18
CA2983250C (en) 2021-04-27
KR20180125865A (ko) 2018-11-26
US20180064722A1 (en) 2018-03-08
JP2018516961A (ja) 2018-06-28
EP3270925A1 (en) 2018-01-24
MY198774A (en) 2023-09-26
CN107835686A (zh) 2018-03-23
RU2017144215A3 (es) 2020-07-30
KR102417756B1 (ko) 2022-07-05
JP6552648B2 (ja) 2019-07-31
ZA201706947B (en) 2019-02-27

Similar Documents

Publication Publication Date Title
MX364942B (es) Peptidos antimicrobianos.
EP3607952A4 (en) USE OF CARRIMYCIN AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND / OR PREVENTION OF TUMORS
BR112017002335A2 (pt) formulações de suspensão oral em pó de agentes antibacterianos
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017013433A (es) Composiciones antibacterianas.
MX2018000092A (es) Nuevo lipolantipeptido biciclico, preparacion y uso como agente antimicrobiano.
PH12018501758A1 (en) Oritavancin formulations
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
MX2017013434A (es) Composiciones antibacterianas.
MX2018011095A (es) Compuestos de carbapenem.
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
MY186775A (en) Antibacterial compositions and methods
EP3691665A4 (en) PHARMACEUTICAL COMPOSITION CONSISTING OF A PROBIOTIC AND A PREBIOTIC FOR PREVENTING OR TREATING DRUG-RESISTANT INFECTIONS
MX2019010112A (es) Compuestos antibacterianos.
PH12016502548A1 (en) Antimicrobial compositions with effervescent agents
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MX2019007390A (es) Peptidos antimicrobianos y usos de los mismos.
UA94988U (xx) Фармацевтична композиція
UA111961U (uk) Антибактеріальна композиція

Legal Events

Date Code Title Description
FG Grant or registration